EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Integrating Anti-Phosphatidylserine/Prothrombin Antibodies Testing into Antiphospholipid Syndrome Diagnostics: A Multidomain, Expert Perception-Based Health Technology Assessment

Michele Cioffi iD, Valentina Oddone, Massimo Radin iD, Irene Cecchi iD, Alice Barinotti, Silvia Grazietta Foddai iD, Nicola Di Gaetano iD, Nicoletta Pagani, Andrea Colmegna, Simone Baldovino iD, Roberta Fenoglio iD, Dario Roccatello und 1 weitere

Diagnostics · 01.02.2026 · 16 (3) · 434

DOI: 10.3390/diagnostics16030434 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Diagnostics, online erschienen am 01.02.2026. Verfasst von Michele Cioffi und 12 weiteren Autor:innen. Beteiligte Einrichtung: University Center of Excellence on Nephrologic, Rheumatologic and Rare Diseases (ERK-Net, ERN-Reconnect and RITA-ERN Member) with Nephrology and Dial…. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Antiphospholipid syndrome (APS) is diagnosed by characteristic clinical manifestations supported by positivity for lupus anticoagulant, anticardiolipin, and anti-β2-glycoprotein I antibodies. However, a proportion of patients, especially those with systemic lupus erythematosus, remain seronegative despite high clinical suspicion. Anti-phosphatidylserine/prothrombin antibodies (aPS/PT) have emerged as potential biomarkers in this setting. We conducted an expert perception-based Health Technology Assessment (HTA) to evaluate the clinical, ethical, and organizational impact of implementing aPS/PT testing.

Methods

A structured HTA was performed across five domains: safety, perceived efficacy, equity, ethics, and organizational implications. A survey was distributed to 110 APS specialists; 50 experts contributed responses (45.5% response rate; 66% clinicians, 18% laboratory personnel, 8% nurses, 8% administrative/other). For each domain, Z-scores were calculated to compare current diagnostic practice (AS IS) with a scenario integrating aPS/PT testing (TO BE). Correlation analyses explored relationships across domains.

Results

Across all five domains, the TO BE scenario scored substantially higher than standard practice. The largest improvements were observed in perceived diagnostic efficacy (ΔZ = +2.65) and safety (ΔZ = +2.03), followed by equity (ΔZ = +2.25), ethical/social impact (ΔZ = +1.96), and organizational feasibility (ΔZ = +1.61). Perceived diagnostic effectiveness showed a strong positive correlation with both equity (r = 0.70, p < 0.001) and ethics (r = 0.67, p < 0.001). Participants consistently rated the assay as safe, clinically useful, equitable, and organizationally easy to introduce in routine laboratory workflows.

Conclusions

Experts perceived the addition of aPS/PT testing as a meaningful enhancement to APS diagnostics, particularly for SLE patients who are seronegative on conventional assays. Its favorable profile across all HTA domains supports further evaluation in prospective cohorts and consideration for integration into future diagnostic algorithms.

Schlagwörter

Stichwörter der Autor:innen

anti-prothrombin antibodiesantiphospholipid antibodiesantiphospholipid syndromehealth technology assessment

Autor:innen und Institutionen

  • University Center of Excellence on Nephrologic, Rheumatologic and Rare Diseases (ERK-Net, ERN-Reconnect and RITA-ERN Member) with Nephrology and Dialysis Unit and Center of Immuno-Rheumatology and Rare Diseases (CMID),…
  • Department of Clinical and Biological Sciences, University of Turin, 10125 Turin, Italy.
  • Werfen, 08908 Barcelona, Spain.

ORCID-Profile: Michele Cioffi, Massimo Radin, Irene Cecchi, Silvia Grazietta Foddai, Nicola Di Gaetano, Simone Baldovino, Roberta Fenoglio, Savino Sciascia

Zitieren

APA

Cioffi, M., Oddone, V., Radin, M., Cecchi, I., Barinotti, A., Foddai, S. G., Di Gaetano, N., Pagani, N., Colmegna, A., Baldovino, S., Fenoglio, R., Roccatello, D., & Sciascia, S. (2026). Integrating Anti-Phosphatidylserine/Prothrombin Antibodies Testing into Antiphospholipid Syndrome Diagnostics: A Multidomain, Expert Perception-Based Health Technology Assessment. Diagnostics, 16(3), 434. https://doi.org/10.3390/diagnostics16030434

Vancouver

Cioffi M, Oddone V, Radin M, Cecchi I, Barinotti A, Foddai SG, et al. Integrating Anti-Phosphatidylserine/Prothrombin Antibodies Testing into Antiphospholipid Syndrome Diagnostics: A Multidomain, Expert Perception-Based Health Technology Assessment. Diagnostics. 2026;16(3):434. doi:10.3390/diagnostics16030434

BibTeX
@article{Cioffi2026,
  author = {Cioffi, Michele and Oddone, Valentina and Radin, Massimo and Cecchi, Irene and Barinotti, Alice and Foddai, Silvia Grazietta and Di Gaetano, Nicola and Pagani, Nicoletta and Colmegna, Andrea and Baldovino, Simone and Fenoglio, Roberta and Roccatello, Dario and Sciascia, Savino},
  title = {Integrating Anti-Phosphatidylserine/Prothrombin Antibodies Testing into Antiphospholipid Syndrome Diagnostics: A Multidomain, Expert Perception-Based Health Technology Assessment},
  journal = {Diagnostics},
  year = {2026},
  volume = {16},
  number = {3},
  pages = {434},
  doi = {10.3390/diagnostics16030434}
}
Kostenlos starten →